Glutathione S-transferase (GST) is a cytosolic enzyme found in high concentrations in the liver. We investigated the value of plasma GST measurements in pre-eclamptic patients. A total of 80 patients (40 in the preeclampsia group and 40 in the control group) were recruited. All patients were evaluated for GST, alanine aminotransferase (ALT), aspartate aminotransferase and lactate dehydrogenase. Pre-eclampsia was defined as the occurrence, after 20 weeks' gestation, of a diastolic blood pressure greater than 90 mmHg on two or more occasions at least 4 h apart, and concomitant proteinuria greater than 0.3 g/l over a 24-h urine collection period. There was no statistical difference between the pre-eclampsia and control groups in terms of ALT, gestational age, maternal age or number of previous pregnancies; a significant difference was found between the pre-eclampsia and control groups in terms of GST. Preeclampsia represents a significant cause of maternal and perinatal morbidity and mortality. Accurate assessment of hepatocellular damage is essential in the clinical management of these patients. GST levels in pre-eclamptic patients were found to be much higher (131.98 IU/l) than in control patients (68.67 IU/l), and this high level suggests hepatocellular damage. We concluded that measurement of plasma GST might provide an earlier and much more sensitive indicator of hepatocellular damage than other liver-function tests.
Measurement of Plasma Glutathione S-transferase in Hepatocellular Damage
in Pre-eclampsia*
Introduction
Pre-eclampsia is one of the most common causes of maternal and perinatal morbidity and mortality. 1 Early diagnosis of pre-eclampsia and liver impairment is extremely important in the prevention of maternal and fetal mortality and morbidity during pregnancy.
The cytosolic liver enzyme, glutathione S-transferase (GST), is an essential marker of hepatocyte damage caused by conditions such as haemorrhagic shock, ischaemia and reperfusion, liver transplant rejection and paracetamol overdose. GST is found in high concentrations (approximately 3 mg/g wet weight) in the liver. 2 -6 Conventional serum liver enzymes such as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) have also been used as markers of hepatic damage. AST is found in high concentrations in heart and skeletal muscle, kidney, pancreas and erythrocytes, as well as in the liver, which makes it an unspecific marker, especially in conditions in which haemolysis is involved. Impairment of hepatic function is an important factor in the clinical management of pre-eclamptic patients and, therefore, accurate assessment of possible hepatic damage is necessary. The standard liver function tests, serum AST and ALT, do not accurately reflect the severity of the underlying histopathological condition in syndromes associated with pre-eclampsia, such as haemolysis, elevated liver enzymes and low platelet count (HELLP). 7, 8 Elevated serum ALT levels are considered to be more specific for hepatic damage than serum AST levels because the concentration of ALT in the liver is relatively high. A sustained elevation of serum ALT levels in patients with the HELLP syndrome has been found, indicating persistent hepatocellular damage. 9 GSTs are efficient catalytic enzymes that play an important role in the detoxification and metabolism of many xenobiotic and endobiotic compounds. Cytosolic GSTs are divided into five classes: α, µ, π, θ and ζ. 10 If hepatocellular damage occurs, enzymes are released in considerable quantities into the blood stream. 11 The half-life of GST in plasma is approximately 1 -2 h 2,12 and raised concentrations in plasma occur more rapidly than changes in AST and ALT (half-lives of 17 h and 47 h, respectively), following hepatocellular damage. 12 No clinical condition other than hepatic disease is known to cause raised plasma concentrations of GST; therefore, plasma measurements of this enzyme may provide a fast, specific and sensitive index of acute hepatocellular damage. 13 In the current study, we investigated the possible advantages of plasma GST concentration measurements over serum ALT and AST activities in the assessment of hepatocellular damage in pre-eclampsia.
Patients and methods
A total of 80 patients, 40 with pre-eclampsia and 40 controls, were recruited. All patients were evaluated for maternal age, gestational age, number of previous pregnancies, mean arterial pressure (MAP), GST, AST, ALT and lactate dehydrogenase (LDH). Patients were assigned to the pre-eclampsia group if, after 20 weeks' gestation, they had a diastolic blood pressure greater than 90 mmHg on two or more occasions at least 4 h apart, and concomitant proteinuria greater than 0.3 g/l over a 24-h urine collection period. The control group was recruited from patients attending the normal antenatal ward at Atatürk University Research Hospital between April 2000 and January 2002. In both groups, women with diabetes mellitus, pre-existing hypertension or renal, haematological or cardiac disease were excluded.
Levels of AST, ALT and LDH were measured in same-day blood samples taken from each patient, and determined in the clinical biochemistry laboratory using standard methods and an automatic analyser (Hitachi ® 717, Boehringer, Mannheim, Germany). Part of each blood sample was centrifuged at 2500 g and separated. Plasma samples were stored at -80°C, prior to measurement of GST activity according to the method of Habig et al., 14 using chlorodinitrobenzene (CDNB) (Aldrich, Steinheim, Germany) as substrate and The formation of GST-CDNB conjugate was monitored by the change in absorbance at 340 nm. One unit of GST activity is the amount of enzyme catalysing the conjugation of 1 µmol substrate per min. Blood pressure was taken with a sphygmomanometer with the patient in the sitting position. Diastolic pressure was recorded at the phase V Korotkoff sound.
All analyses were performed using the MINITAB ® (Minitab Inc., State College, PA, USA) Statistical Program, version 9.2. Comparisons between the pre-eclampsia and control groups were evaluated using the unpaired t-test. P < 0.05 was considered statistically significant.
Results
Even though ALT, AST and LDH levels in the pre-eclampsia group were found to be a little higher than in the control group, these differences were not statistically significant. A significant difference (P < 0.01) in GST was found between the pre-eclampsia and control groups (Table 1 and Fig. 1 ).
Maternal age, gestational age, number of previous pregnancies and MAP are summarized in Table 2 . There were no statistical differences between the preeclampsia and control groups in terms of maternal age and number of previous pregnancies. A statistically significant difference (P < 0.01) was determined between the pre-eclampsia and control groups in terms of gestational age (34.3 ± 3.6 weeks and 36.1 ± 4.7 weeks, respectively), but this factor is not associated with changes in values of hepatic enzymes. 1
Discussion
Glutathione S-transferase is a sensitive marker for the assessment of hepatocellular damage compared with transaminases. 2 It is distributed uniformly throughout the liver compared with the transaminases, which are found predominantly in the periportal hepatocytes, and may therefore be useful in detecting centrilobular damage. 15 It has a relatively small molecular weight and is released readily and rapidly into the circulation following hepatocellular damage. The cause of impaired hepatocellular integrity in pre-eclampsia is not fully understood, but may be the result of increased hepatic artery resistance and microthrombosis in hepatic vessels, both of which may cause hepatic tissue necrosis. 16, 17 Accurate assessment of hepatocellular damage is essential in the clinical management of patients with pre-eclampsia. When hepatocellular damage occurs, circulating GST levels increase immediately. Knapen et al. 1 found that increases in GST levels were these high levels are suggestive of hepatocellular damage. Measurement of plasma GST might provide an earlier and much more sensitive indicator of acute hepatocellular damage, as well as of its resolution, in preeclampsia and other conditions causing hepatic damage, such as HELLP syndrome, septic shock and paracetamol overdose, than the ALT liver-function test. 6, 18 As a result of the higher concentration (3 mg/g wet weight 2 ) of GST than AST and ALT in the liver, the plasma level of GST increases earlier than AST and ALT when hepatocellular damage takes place. In addition, while GST significantly higher in patients with preeclampsia than in normotensive pregnancies: the medians in normotensive pregnancy, preeclampsia and HELLP syndrome were 1.0, 4.1 and 131.7, respectively. It was also found that plasma elevation of GST occurred earlier than that of ALT in patients with HELLP syndrome, with a magnitude of elevation approximately 500 times higher than in controls while patients were experiencing epigastric pain. 10 Among our pre-eclampsia patients, none had HELLP syndrome, but we found that their GST levels were approximately twice those (132.0 IU/l) in control patients (68.8 IU/l), and • Received for publication 20 April 2002 • Accepted 20 May 2002 ©2002 Cambridge Medical Publications appears in the centrilobular hepatocytes, ALT and AST are only present in the periportal region. We also determined that although AST, ALT and LDH levels were slightly higher in the pre-eclampsia patients than in the control group, the differences were not statistically significant.
In conclusion, determination of plasma GST levels provides an earlier and more sensitive diagnosis of acute hepatocellular damage in pre-eclampsia than AST and ALT, and may also give an indication of its resolution.
